Last reviewed · How we verify
Qapzola
Qapzola is a Small molecule drug developed by Spectrum Pharmaceuticals, Inc. It is currently in discontinued development.
At a glance
| Generic name | Qapzola |
|---|---|
| Sponsor | Spectrum Pharmaceuticals, Inc |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Randomized, Placebo-controlled, Double-blinded Study of Single Immediate Instillation of EO9 After TURBT in Patients With NMIBC (Phase 2)
- A Phase 3 International, Double-Bind Trial Evaluating Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients With Low-Intermediate Risk Non-Muscle Invasive Bl (Phase 3)
- Phase II Study of Intravesical Instillation of EOQUIN™ in High Risk Superficial Bladder Cancer (Phase 2)
- A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patien (Phase 3)
- A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patien (Phase 3)
- A Multicenter, Multi-Arm, Randomized, Multi-Dose, Placebo-Controlled, Double-Blind, Phase 3 Study of Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant in the Immediate Postoperative Period in P (Phase 3)
- A Phase 3 International, Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial Evaluating the Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients (Phase 3)
- A Randomized, Multicenter, Two-Arm, Single-Dose, Double-Blind, Placebo-CONtrolled Phase 3 Study of Intravesical Qapzola™ (Apaziquone) as a Chemotherapy Adjuvant to TransUrEthral Resection of Bladder T (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Qapzola CI brief — competitive landscape report
- Qapzola updates RSS · CI watch RSS
- Spectrum Pharmaceuticals, Inc portfolio CI
Frequently asked questions about Qapzola
What is Qapzola?
Qapzola is a Small molecule drug developed by Spectrum Pharmaceuticals, Inc.
Who makes Qapzola?
Qapzola is developed by Spectrum Pharmaceuticals, Inc (see full Spectrum Pharmaceuticals, Inc pipeline at /company/spectrum-pharmaceuticals-inc).
What development phase is Qapzola in?
Qapzola is in discontinued.
Related
- Manufacturer: Spectrum Pharmaceuticals, Inc — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing